CIS
VRTX icon

Capital International Sarl’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital International Sarl’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105M Buy
210,718
+1,836
+0.9% +$814K 1.48% 16
2026
Q1 		$93.3M Buy
208,882
+15,444
+8% +$7.2M 1.53% 14
2025
Q4 		$87.7M Sell
193,438
-32,296
-14% -$13.9M 1.41% 15
2025
Q3 		$88.4M Buy
225,734
+2,345
+1% +$980K 1.53% 15
2025
Q2 		$99.5M Buy
223,389
+37,218
+20% +$17.2M 1.91% 9
2025
Q1 		$90.3M Buy
186,171
+17,579
+10% +$8.19M 2.04% 9
2024
Q4 		$67.9M Buy
168,592
+25,544
+18% +$11.8M 1.57% 12
2024
Q3 		$66.5M Buy
143,048
+18,968
+15% +$9.11M 1.71% 9
2024
Q2 		$58.2M Buy
124,080
+7,602
+7% +$3.3M 1.78% 10
2024
Q1 		$48.7M Buy
116,478
+22,891
+24% +$9.68M 1.61% 9
2023
Q4 		$38.1M Buy
93,587
+14,113
+18% +$5.21M 1.43% 10
2023
Q3 		$27.6M Buy
79,474
+5,799
+8% +$2.03M 1.26% 17
2023
Q2 		$25.9M Buy
73,675
+15,253
+26% +$5.14M 1.16% 16
2023
Q1 		$18.4M Buy
58,422
+7,652
+15% +$2.3M 0.93% 28
2022
Q4 		$14.7M Buy
50,770
+3,057
+6% +$932K 1.03% 22
2022
Q3 		$13.8M Buy
47,713
+4,461
+10% +$1.28M 1.12% 16
2022
Q2 		$12.2M Buy
43,252
+1,225
+3% +$328K 0.98% 17
2022
Q1 		$11M Sell
42,027
-4,528
-10% -$1.07M 0.54% 53
2021
Q4 		$10.2M Buy
46,555
+33,939
+269% +$6.6M 0.49% 60
2021
Q3 		$2.29M Sell
12,616
-2,214
-15% -$432K 0.2% 123
2021
Q2 		$2.99M Buy
14,830
+341
+2% +$71.3K 0.26% 106
2021
Q1 		$3.11M Buy
14,489
+374
+3% +$82.1K 0.3% 93
2020
Q4 		$3.34M Buy
14,115
+393
+3% +$90.2K 0.35% 87
2020
Q3 		$3.73M Buy
13,722
+536
+4% +$148K 0.46% 70
2020
Q2 		$3.83M Buy
13,186
+2,424
+23% +$657K 0.51% 59
2020
Q1 		$2.56M Buy
10,762
+3,188
+42% +$731K 0.47% 64
2019
Q4 		$1.66M Buy
+7,574
New +$1.53M 0.26% 104

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Capital International Sarl's VRTX Position: Q2 2026 in Review

Capital International Sarl increased its Vertex Pharmaceuticals (VRTX) stake by 0.88% in Q2 2026, buying an estimated $814K and bringing the position to 210,718 shares worth $105M. The position accounts for 1.48% of the portfolio, ranked #16.

Capital International Sarl first reported a position in VRTX in Q4 2019 and has held it in 27 quarters since. 1,754 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Capital International Sarl held 210,718 shares of Vertex Pharmaceuticals worth $105M as of Q2 2026.
  • Capital International Sarl bought 1,836 Vertex Pharmaceuticals shares in Q2 2026, an estimated $814K.
  • Vertex Pharmaceuticals made up 1.48% of Capital International Sarl's portfolio in Q2 2026, its #16 holding.
  • Capital International Sarl first reported a position in Vertex Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • 1,754 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital International Sarl's 13F filing for Q2 2026, filed 12 Aug 2026.